Press release
Increase in the prophylactic and therapeutic Cytomegalovirus Infection Market is anticipated for the study period, 2019-2032
Recent Developmental Activities in the Cytomegalovirus Infection Treatment Landscape
• mRNA-1647 being developed by ModernaTX comprises six mRNAs encoding two antigens in one vaccine and is designed to protect against CMV infection. Unlike a protein-based vaccine, mRNA-1647 instructs the body's own cells to manufacture the antigens, resulting in functional antigens that mimic those presented to the immune system by CMV during a natural infection. Preclinical data previously published in Vaccine showed that vaccination with mRNA-1647 in animal models elicited potent and durable neutralizing antibody titers. The mRNA-1647 is in phase III investigational stage.
• NPC-21 (EV2038) is a fully human monoclonal antibody that targets the antigenic domain 1 of glycoprotein B on the human cytomegalovirus (hCMV) envelope. NPC-21 has been shown to have broadly neutralizing activity and to inhibit cell-to-cell transmission of hCMV in preclinical studies. It is currently in phase II development for the prophylactic or preemptive treatment of hCMV in patients receiving a solid-organ transplant or hematopoietic stem cell transplant. Nobelpharma has partnered with Evec for the development of NPC-21 (EV2038) and according the company it is expected for a market authorization by 2027.
Explore more information about the Latest Drugs Launch, New Breakthroughs of Drugs or Therapies Approach, Treatment Practices, and Forecasted Epidemiology @ Cytomegalovirus Infection Market Size Report- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cytomegalovirus Infection Overview
Cytomegalovirus (CMV) Infections is a type of herpesvirus (herpesvirus type 5) with a wide range of symptoms: from no symptoms to fever and fatigue (resembling infectious mononucleosis) to severe
symptoms involving the eyes, brain, or other internal organs. It is a common virus for people of all ages; however, a healthy person's immune system usually keeps the virus from causing illness. Blood tests show that 60-90% of adults have had a CMV Infections infection at some time.
Key Takeaways from the Cytomegalovirus Infection Market Report
• The market is expected to grow by factors like an increase in the patient population, and expected entry of emerging therapies.
• According to DelveInsight, Cytomegalovirus Infection Infections affects males and female equally.
• The leading Cytomegalovirus Infection Companies include Takeda, Merck & Co, Nobel pharma, and others
• Promising Cytomegalovirus Infection Pipeline Therapies include NPC-21 (EV2038), PREVYMIS, LIVTENCITY, and others
Cytomegalovirus Infection Epidemiology Segmentation in the 7MM
• Total Cytomegalovirus Infection Diagnosed Cases
• Cytomegalovirus Infection Retinitis among HIV Patients
• Cytomegalovirus Infection Number of Refractory Patients after HS CT/SOT
• Cytomegalovirus Infection Number of Infants Born
• Cytomegalovirus Infection Patients among Hematopoietic Stem Cell Transplants
• Cytomegalovirus Infection Number of Patients among SOT
Download the report to understand which factors are driving Cytomegalovirus Infection epidemiology trends @ Cytomegalovirus Infection Epidemiological Insights- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Cytomegalovirus Infection Market Insights
Cytomegalovirus Infection or reactivation can lead to serious complications in hosts whose immune systems are either compromised by disease or suppressed, which is common following stem cell and solid organ transplants. The treatment market of Cytomegalovirus Infection is divided into Prophylactic Drugs and Therapeutic Drugs.
Cytomegalovirus Infection Market Size
The Cytomegalovirus Infection market size is expected to grow during the forecast period owing to the expected launch of novel emerging therapies for treatment and prevention, which shall fuel the growth of the market during the forecast period, i.e., 2023-2032. "Cytomegalovirus Infection represents a significant unmet medical need and can lead to lifelong medical conditions for those with weakened medical circumstances or those born with CMV infection." There is no FDA approved vaccine to prevent CMV.
Learn more about the FDA-approved drugs for Cytomegalovirus Infection @ Cytomegalovirus Infection Market Drivers and Barriers- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Cytomegalovirus Infection Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Cytomegalovirus Infection Companies- Takeda, Merck & Co, Nobel pharma, and others
• Cytomegalovirus Infection Pipeline Therapies include NPC-21 (EV2038), PREVYMIS, LIVTENCITY, and others
• Cytomegalovirus Infection Market Dynamics: Cytomegalovirus Infection Market Drivers and Barriers
• Cytomegalovirus Infection Market Access and Reimbursement, Unmet Needs, and Emerging Drugs
Discover more about Cytomegalovirus Infection Drugs in development @ Cytomegalovirus Infection Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Executive Summary of Cytomegalovirus (CMV) Infection
3. Competitive Intelligence Analysis for Cytomegalovirus (CMV) Infection
4. Cytomegalovirus (CMV) Infection: Market Overview at a Glance
5. Cytomegalovirus (CMV) Infection: Disease Background and Overview
6. Patient Journey
7. Cytomegalovirus (CMV) Infection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Cytomegalovirus (CMV) Infection Unmet Needs
10. Key Endpoints of Cytomegalovirus (CMV) Infection Treatment
11. Cytomegalovirus (CMV) Infection Marketed Products
12. Cytomegalovirus (CMV) Infection Emerging Therapies
13. Cytomegalovirus (CMV) Infection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Cytomegalovirus (CMV) Infection
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Got Queries? Reach out for more information about the Patient Population, Treatment Algorithm, Unmet Needs, and Emerging Drugs of the report @ Cytomegalovirus Infection Market Dynamics Report- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Contact Us
Yash Bhardwaj
info@delveinsight.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Increase in the prophylactic and therapeutic Cytomegalovirus Infection Market is anticipated for the study period, 2019-2032 here
News-ID: 3047805 • Views: …
More Releases from DelveInsight Business Research
Niemann-Pick Type C Pipeline Report Showcases Emerging Drugs and Leading Compani …
DelveInsight's, "Niemann Pick C Disease Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 15+ pipeline drugs in Niemann Pick C Disease pipeline landscape. It covers the Niemann-Pick Type C pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Niemann-Pick Type C pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this…
Pemphigus Vulgaris Market Positioned for Accelerated Development Through 2034, D …
DelveInsight's "Pemphigus Vulgaris Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Pemphigus Vulgaris, historical and forecasted epidemiology as well as the Pemphigus Vulgaris market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Pemphigus Vulgaris market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pemphigus Vulgaris Market Forecast
https://www.delveinsight.com/sample-request/pemphigus-vulgaris-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Osteogenesis Imperfecta Market to Evolve Rapidly Over the Next Decade by 2034, D …
The Osteogenesis Imperfecta market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteogenesis Imperfecta pipeline products will significantly revolutionize the Osteogenesis Imperfecta market dynamics.
DelveInsight's "Osteogenesis Imperfecta Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Osteogenesis Imperfecta, historical and forecasted epidemiology as well as the Osteogenesis Imperfecta market trends in the United…
Myopic Macular Degeneration Market Insights Highlight Expanding Outlook Till 203 …
DelveInsight's "Myopic Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myopic Macular Degeneration, historical and forecasted epidemiology as well as the Myopic Macular Degeneration market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Myopic Macular Degeneration, offering comprehensive insights into the Myopic Macular Degeneration revenue trends,…
More Releases for Cytomegalovirus
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus Retinitis Market Forecast 2031: Growth and Opportunities
The "Cytomegalovirus Retinitis Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Cytomegalovirus Solutions Soar: Cytomegalovirus Treatment Market Targets US$ 326 …
The Cytomegalovirus (CMV) Treatment Market stands at the forefront of addressing a formidable viral adversary that often operates under the radar. Cytomegalovirus, a member of the herpesvirus family, can pose serious threats to individuals with weakened immune systems, such as transplant recipients and those living with HIV. As a result, the development of effective treatments has become a critical endeavor in the realm of infectious diseases.
In 2022, the global cytomegalovirus…
Cytomegalovirus Treatment Market Will Generate Record Revenue by 2029
The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%-56.0% in SOT recipients and 30.0%-70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in…
Cytomegalovirus Diagnostics Market Research Insights, Trends Forecast 2022-28
The global cytomegalovirus diagnostics market size was valued at USD 73.6 million in 2021, growing at a CAGR of 6.1% during the forecast period 2022-28. A common herpesvirus called cytomegalovirus can produce a wide range of symptoms, from little to no symptoms to fever and tiredness to severe symptoms affecting the brain, eyes, and other internal organs. Plasma, sperm, saliva, urinalysis, and breast milk can all be used as…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
